Skip to main content Skip to section navigation Skip to footer
180 Life Sciences Corp.
  • Home
  • Home
  • About Us
  • Programs
    • Anti-TNF
    • Synthetic CBD Analogs (SCAs)
    • a7nAChR Program
  • Pipeline
  • Leadership
  • Investors
  • Contact Us
  • Contact Us

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Overview
    • Management Team
    • Presentations
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Email Alerts
Sep 12, 2024 4:15pm EDT

180 Life Sciences Announces the Appointment of Omar Jimenez as Chief Financial Officer

Jul 30, 2024 8:00am EDT

180 Life Sciences Announces Positive Topline Results of a Clinical Pharmacology Study Testing a New Solid Formulation of CBD with Enhanced Oral Uptake

Jul 23, 2024 8:00am EDT

180 Life Sciences Granted an Additional Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements

Jul 02, 2024 8:30am EDT

180 Life Sciences Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements

Mar 14, 2024 8:30am EDT

180 Life Sciences Regains Full Compliance with Nasdaq Minimum Bid Price Requirement

Feb 26, 2024 7:00am EST

180 Life Sciences Corp. Announces 1-For 19 Reverse Stock Split as Part of Nasdaq Compliance Plan

Dec 04, 2023 9:00am EST

180 Life Sciences Engages Financial Advisor to Explore Strategic Alternatives

Nov 28, 2023 9:00am EST

180 Life Sciences Announces Review of Strategic Alternatives

Aug 14, 2023 4:29pm EDT

180 Life Sciences Corp. Announces Closing of $3 Million Public Offering

Aug 10, 2023 8:46am EDT

180 Life Sciences Corp. Announces Pricing of $3 Million Public Offering

  • Previous Pagearrow_back
  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • Page 10
  • Next Pagearrow_forward
rss_feed News RSS
  • Email Alerts
  • Contacts
  • RSS News Feed
© Copyright 2012 - 2025 | 180 Life Sciences Corp. | All Rights Reserved.
  • Visit us on Twitter Twitter
  • Visit us on Linkedin Linkedin